is this why stock is down today ? So this means just meeting end point not good enough..they have to show strong results. But with mid dose, drug did not work. Lots of ifs here.
no wonder insiders have been unloading since Dec. They are also being careful.
If cldn needs to go a phase III, stock will tank.
we have been guiding for the last recent months, that if we just barely crossed the finish line in terms of having a P, just barely under 0.05, that we think a subsequent trial will be required. The EMA essentially has verified that.
they don't know the results till April too. It goes straight to the FDA. But it is clear they are cautious and have starting unloading since in the 15s. Shows their confidence is not 100% sure. Could be because lower doses actually did not work. And higher doses were tilted towards favorable outcome.
this is old news...go look at their website...this was already said in their last release too. No guarantee about results. Even they don't know..it is blinded test.
fair value of CLDN should be 100 easy given total market.
dude biotechs ONLY trade on bullishness..that is by BLUE, KITE JUNO are worth multi billions without any product or even a phase 2 out yet.
not really..just simple profit taking. fresh money will start adding to this. The story remains the same, and the stock is very undervalued going into April and data.
go to seeking alpha..there is a writeup there too. also motley fool article search it up.
this is just profit taking...you know it, everyone knows it. stock is still way undervalued at over 1.5to 2 billion peak sales for this unmet medical need. Read about this in MF article.
If they get approval (very low bar to cross...its in the article), FDA approval will be very quick with blockbuster status..which is why they are ramping up manufacturing to be ready.
Stock will take a bit breather and top 30 by 1st week April. Time to get in is now.
fresh money has been waiting for this pullback..
so soon...see it above 30 by end of March.
to CLDN, market cap only $600M, much more cutting edge gene therapy, big market, big costs per procedure.
totally agree...they already confirmed in Feb conf that they are on track for April...that will be reconfirmed end of March. Nothing else matters.
I don't think it will go 150-200..but will go over 60 for sure. This is a double and give market cap about 1.5 billion. That is about right. Once FDA approves (which will be quick) will see 80 or so.
Stock will be about 32-34 before results are out in April.
Even minor minor dips are being bought...
bet on it.